Top Story Today
Three Buyouts, One Week, $5.75 Billion: The M&A Dam Finally Burst
Three biotech acquisitions landed in a single week, totaling approximately $5.75 billion in disclosed value. The capstone: Italy's Chiesi Group paying $1.9 billion for KalVista, maker of the first oral pill for acute hereditary angioedema attacks. The deal wave included buyers chasing the same playbook: buy approved or late-stage drugs at full price rather than wait a decade for internal R&D to deliver. Commercial-stage assets now account for nearly half of all 2026 M&A value.
Why it matters: Big pharma's patent cliffs are approaching fast, and the message from boardrooms is clear: de-risked pipelines with real revenue command premium prices. Oral delivery, rare disease exclusivity, and near-term cash flow have become the holy trinity of acquisition targets.
Read more →Deals & M&A
Italy's Angelini Drops $4.1 Billion on a Florida Rare Disease Company
A 107-year-old Italian pharma just made its biggest acquisition ever, buying Catalyst Pharmaceuticals for $4.1 billion in cash. The prize: FIRDAPSE, essentially the only drug for an ultra-rare nerve disorder called LEMS, generating $358.4 million in net product revenue in 2025. A same-day patent settlement locks out generics until 2035, giving Angelini nearly a decade of protected U.S. cash flow.
Read more →Roche Pays $1 Billion for a Pathologist That Never Sleeps
Roche agreed to acquire AI pathology firm PathAI for up to $1.05 billion ($750 million upfront, $300 million in milestones). PathAI's software reads cancer tissue slides with AI trained on 32.5 million expert annotations. Roche gets a complete infrastructure layer for computational pathology, plugged into its diagnostics network spanning 100+ countries.
Read more →Funding & Financings
The Biotech IPO That Came Back From the Dead
Odyssey Therapeutics pulled its IPO in 2025 when biotech markets froze. This week it raised $304 million in an upsized offering at the top of its price range. The autoimmune-focused company used the downtime to raise a $213 million Series D and push its lead drug into Phase 2, showing up to Wall Street's door as a fundamentally different company.
Read more →Blackstone Bets $250 Million That CF Patients Shouldn't Swallow 40 Pills a Day
Blackstone Life Sciences invested $250 million in Anagram Therapeutics, which is building an oral enzyme that could replace the many daily capsules cystic fibrosis patients take just to digest food. The company claims some patients take as many as 40 pills per day, and aims to cut that down to three. Funding covers development through commercial launch.
Read more →Clinical & Pipeline
IL-2 Immunotherapy Continues to Struggle Toward Commercial Success
IL-2 immunotherapy remains one of oncology's most tantalizing yet elusive targets. The field has burned through billions — including BMS/Nektar's $3.65 billion deal and Sanofi's $2.5B Synthorx buy — without producing a commercial winner. Multiple programs have been abandoned over the years as companies struggle to tame IL-2's toxic side effects while preserving its anti-tumor potency.
Read more →